ReviewBiomedicines2022
Gastric Cancer: Mechanisms, Biomarkers, and Therapeutic Approaches.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Global research trends and emerging hotspots of immune checkpoint inhibitors in gastric cancer from 2015 to 2025.Discover oncology · 2026Article
- Human Epidermal Growth Factor Receptor 2-Positive, Claudin-18 Isoform 2-Positive, Mismatch Repair-Deficient Gastric Cancer Revealed by Immunohistochemical Analysis of Surgical Specimens: A Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- Successful non-surgical management of locally advanced gastric adenocarcinoma with squamous differentiation and programmed death-ligand 1 combined positive score 75: a case report.Journal of medical case reports · 2026Article
- Comprehensive Overview of Gastric Cancer Immunohistochemistry: Key Biomarkers, Advanced Detection Methods, and Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- Bioorthogonal catalytic centres engineered for gastrointestinal stabilization provide oral delivery for the treatment of gastric cancer.Journal of nanobiotechnology · 2026Article
- Rethinking biomarker strategy in gastric cancer immunotherapy: from tumor to host.Frontiers in immunology · 2026Review
- Progress of immune checkpoint inhibitors in gastric cancer.World journal of gastrointestinal oncology · 2025Review
- Double optimal transport for differential gene regulatory network inference with unpaired samples.Bioinformatics (Oxford, England) · 2025Article
- Promising Gastric Cancer Biomarkers-Focus on Tryptophan Metabolism via the Kynurenine Pathway.International journal of molecular sciences · 2025Review
- Advances and challenges in gastric cancer testing: the role of biomarkers.Cancer biology & medicine · 2025Review
- Lower cytoplasmic expression of DDIT4 is associated with poor prognosis in gastric cancer patients.Discover oncology · 2025Article
- Big Data and Artificial Intelligence in Drug Discovery for Gastric Cancer: Current Applications and Future Perspectives.Current medicinal chemistry · 2025Review
- Artificial intelligence in advanced gastric cancer: a comprehensive review of applications in precision oncology.Frontiers in oncology · 2025Review
- Metagenomic analysis and bioactive profiling of kombucha fermentation: antioxidant, antibacterial activities, and molecular docking insights into gastric cancer therapeutics.Toxicology research · 2024Article
- A predictive and prognostic model for metastasis risk and prognostic factors in gastrointestinal signet ring cell carcinoma.European journal of medical research · 2024Article
- Best Practices for Managing Patients with Unresectable Metastatic Gastric and Gastroesophageal Junction Cancer in Canada.Current oncology (Toronto, Ont.) · 2024Review
- Comparison of nalbuphine and dezocine for postoperative analgesia in elderly patients undergoing laparoscopic radical gastric cancer surgery.American journal of translational research · 2024Article
- Article
- Implementing an On-Slide Molecular Classification of Gastric Cancer: A Tissue Microarray Study.Cancers · 2023Article
- PRMT1 promotes the proliferation and metastasis of gastric cancer cells by recruiting MLXIP for the transcriptional activation of the β-catenin pathway.Genes & diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gastric cancer (GC) remains one of the most common deadly malignancies worldwide. Recently, several targeted therapeutics for treating unresectable or metastatic GC have been developed. Comprehensive characterization of the molecular profile and of the tumor immune microenvironment of GC has allowed researchers to explore promising biomarkers for GC treatment and has enabled a new paradigm in precision-targeted immunotherapy. In this article, we review established and promising new biomarkers relevant in GC, with a focus on their clinical implications, diagnostic methods, and the efficacy of targeted agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.